INMB Inmune Bio, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1711754 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY257.1%
TTM net income YoY-9.2%
TTM EPS YoY11.8%
Revenue 3-yr CAGR-48.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-94,766.0%
Net margin-91,866.0%
FCF margin—
EBITDA margin—
Returns
ROE-165.2%
ROA-127.7%
ROIC (approx.)-300.1%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets27.3%
Debt / equity0.00x
Current ratio3.55x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.49x
Accruals ratio-64.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $50,000 | $14,000 |
| R&D expense | $20.66M | $33.17M |
| SG&A expense | $10.26M | $9.48M |
| Operating income | -$47.38M | -$42.63M |
| Interest expense | $0 | $789,000 |
| Pretax income | $45.93M | $42.08M |
| Net income | -$45.93M | -$42.08M |
| EBITDA | -$47.30M | — |
| EPS (basic) | -1.86 | -2.11 |
| EPS (diluted) | -1.86 | -2.11 |
| Weighted avg. shares (diluted) | 24.76M | 19.94M |
| Balance sheet | ||
| Cash & equivalents | $24.75M | $20.92M |
| Receivables | $4.28M | $1.18M |
| Current assets | $29.89M | $22.66M |
| PP&E, net | $955,000 | — |
| Intangibles | — | $16.51M |
| Total assets | $32.35M | $39.56M |
| Current liabilities | $8.42M | $7.22M |
| Long-term debt | — | $15.00M |
| Total debt | — | $15.00M |
| Total liabilities | $8.83M | $7.46M |
| Shareholders' equity | $23.52M | $32.10M |
| Net debt | — | -$5.92M |
| Shares outstanding | 26.59M | 22.28M |
| Cash flow statement | ||
| Operating cash flow | -$22.58M | -$33.36M |
| Capital expenditure | $1.04M | — |
| Free cash flow | -$23.62M | — |
| Investing cash flow | -$1.04M | — |
| Financing cash flow | $27.61M | $18.21M |
| Depreciation & amortization | $84,000 | — |
| Stock-based compensation | $9.91M | $7.61M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.